Polycythemia Vera

Molecular Defect Test for PV Could Be Malignancy Model

Published in Blood Weekly, April 13th, 1998

A potential definitive test for polycythemia vera, a malignant blood disorder, may serve as a model for identifying the origins of malignant disease.

Polycythemia vera (PV) is marked by a great increase in the number of red cells in the blood, resulting in headaches and potentially fatal blood clots. It usually is treated by a modern form of bloodletting, although more severe cases may require chemotherapy.

A unique molecular defect in the unusual blood disorder, first identified and described at Johns Hopkins by the late Sir William Osler almost a century ago, has been discovered by a team of his professional descendants. The molecular defect that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1998-04-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry